132 related articles for article (PubMed ID: 23393122)
1. Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer.
Park S; Kim IR; Baek KK; Lee SJ; Chang WJ; Maeng CH; Hong JY; Choi MK; Kim YS; Sun JM; Ahn JS; Park K; Jo J; Jung SH; Ahn MJ
Ann Oncol; 2013 Jun; 24(6):1630-9. PubMed ID: 23393122
[TBL] [Abstract][Full Text] [Related]
2. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
3. Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.
Morabito A; Piccirillo MC; Maione P; Luciani A; Cavanna L; Bonanno L; Filipazzi V; Leo S; Cinieri S; Morgillo F; Burgio MA; Ferrara D; Rosetti F; Bianco R; Artioli F; Cortinovis D; Gebbia V; Fregoni V; Mencoboni M; Sandomenico C; Rossi A; Montanino A; Manzo A; Rocco G; Arenare L; Daniele G; Signoriello S; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2019 Jul; 133():62-68. PubMed ID: 31200830
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
6. Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Sztankay M; Giesinger JM; Zabernigg A; Krempler E; Pall G; Hilbe W; Burghuber O; Hochmair M; Rumpold G; Doering S; Holzner B
BMC Cancer; 2017 Aug; 17(1):565. PubMed ID: 28835219
[TBL] [Abstract][Full Text] [Related]
7. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
J Natl Cancer Inst; 1999 Jan; 91(1):66-72. PubMed ID: 9890172
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Bezjak A; Lee CW; Ding K; Brundage M; Winton T; Graham B; Whitehead M; Johnson DH; Livingston RB; Seymour L; Shepherd FA
J Clin Oncol; 2008 Nov; 26(31):5052-9. PubMed ID: 18809617
[TBL] [Abstract][Full Text] [Related]
9. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of Radical Resected NSCLC by Chinese Medicine Combined with Adjuvant Chemother- apy: a Clinical Study].
Hou WX; Li HG; Chen ZW; Zhu LH; Zhao LH; Tian JH; Xu WJ; Zhou L; Yao YL
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jun; 35(6):648-53. PubMed ID: 26242112
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer: The JIPANG Study Protocol.
Yamamoto N; Kenmotsu H; Yamanaka T; Nakamura S; Tsuboi M
Clin Lung Cancer; 2018 Jan; 19(1):e1-e3. PubMed ID: 28668204
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.
Couillard-Montminy V; Gagnon PY; Fortin S; Côté J
J Oncol Pharm Pract; 2019 Jan; 25(1):44-51. PubMed ID: 28825377
[TBL] [Abstract][Full Text] [Related]
15. The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer.
van der Kloot WA; Uchida Y; Inoue K; Kobayashi K; Yamaoka K; Nortier HW; Kaptein AA
Chin Clin Oncol; 2016 Feb; 5(1):3. PubMed ID: 26932427
[TBL] [Abstract][Full Text] [Related]
16. [Quality of life assessment in patients with non-small cell lung cancer treated surgically or with pre-operative chemotherapy followed by surgery].
Wachowicz M; Furmanik F
Pneumonol Alergol Pol; 2003; 71(3-4):121-31. PubMed ID: 14587417
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
Maneechawakajorn J; Hathaisanguan S
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S175-81. PubMed ID: 27266233
[TBL] [Abstract][Full Text] [Related]
18. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
Dancey J; Shepherd FA; Gralla RJ; Kim YS
Lung Cancer; 2004 Feb; 43(2):183-94. PubMed ID: 14739039
[TBL] [Abstract][Full Text] [Related]
19. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
20. Treatment Satisfaction of Patients With Advanced Non-Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL).
Visser S; de Mol M; Cheung K; van Toor JJ; van Walree NC; Stricker BH; Den Oudsten BL; Aerts JGJV
Clin Lung Cancer; 2018 Jul; 19(4):e503-e516. PubMed ID: 29705017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
